Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31069352 | 0.94 | CNR2 (0.41) | CNR2CYP3A4BCHEACHE | |
| SCHEMBL31069353 | 0.93 | CNR2 (0.38) | CNR2CYP3A4 | |
| SCHEMBL6244730 | 0.89 | CYP3A4 (0.56) | CNR2CYP3A4BCHE | |
| SCHEMBL31069286 | 0.89 | CYP3A4 (0.56) | CNR2CYP3A4BCHE | |
| SCHEMBL6276891 | 0.85 | CNR2 (0.40) | CNR2BCHEACHE | |
| SCHEMBL6244317 | 0.82 | TSHR (0.46) | CNR2BCHEACHETSHRMAPK1 | |
| SCHEMBL31069303 | 0.82 | CYP3A4 (0.42) | CYP3A4 | |
| SCHEMBL31069341 | 0.81 | CYP3A4 (0.40) | CYP3A4 | |
| SCHEMBL31069380 | 0.81 | CYP3A4 (0.41) | CYP3A4 | |
| SCHEMBL31069336 | 0.81 | CYP3A4 (0.45) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | CNR2 4156/4885CYP3A4 215/4885BCHE 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.